What TECNIS Odyssey is
TECNIS Odyssey is Johnson & Johnson's newest presbyopia-correcting intraocular lens (IOL), rolled out in the US starting in 2024 as the company's next-generation full-range-of-vision option. The manufacturer describes it as combining design elements from both its diffractive multifocal and extended depth-of-focus (EDOF) platforms — a proprietary echelette (fine concentric ring) structure with roughly 50% shallower step heights than earlier TECNIS multifocal designs, intended to distribute light across distance, intermediate, and near vision while reducing the light scatter that causes halos and glare at night. It is available in both non-toric and toric (astigmatism-correcting) versions, and by late 2025 J&J reported over 100,000 Odyssey lenses implanted worldwide.
What it looks like
Odyssey's echelette optic is a proprietary design. We'd previously checked the FDA's public filings, the manufacturer's newsroom and press pages, distributor listings, and the open peer-reviewed literature, and found no independently published photograph — the only real product photography we could find lived behind the manufacturer's professional-only portal, restricted to healthcare providers. The photo above is different: it's Johnson & Johnson's own product photography, released publicly through its official press materials for the Odyssey launch rather than that professional-only portal. Worth noting plainly — this is a manufacturer-supplied image, not an independent one, so it shows the lens as the company chose to present it.
Where the data on this page comes from
This is worth stating plainly, because it's different from the other reviews on this site. TECNIS PureSee, Synergy, PanOptix, and Vivity were each approved under an FDA PMA supplement that came with a published Summary of Safety and Effectiveness Data (SSED) — a public document containing the full randomized registration-trial tables. Odyssey has also been through FDA PMA review (as a supplement under P980040, the same TECNIS platform approval), but as of this writing, FDA has not published a standalone SSED document with clinical trial tables specifically for Odyssey the way it has for those four lenses.
In place of that, the figures below come from two independent, peer-reviewed retrospective studies published in Clinical Ophthalmology (Dove Medical Press, 2026): a 30-patient (60-eye) general cataract-surgery cohort, and a separate 26-patient (52-eye) cohort of patients with mild-to-moderate primary open-angle glaucoma. Both were investigator-initiated studies funded by a Johnson & Johnson grant, with conflicts of interest disclosed in the published papers — genuinely peer-reviewed and citable, but smaller, shorter, and less independent than a full FDA registration trial. We've used these in place of the manufacturer's own larger marketing figures (small internal "Data on File" studies of 33 and 96 eyes, reporting 92–97% satisfaction rates) specifically because the peer-reviewed studies can be checked by anyone, while "Data on File" cannot.
Visual acuity, across two independent studies
Both studies measured the percentage of patients reaching a threshold level of uncorrected and corrected acuity at distance and at 40 cm near. Note that the two studies used different acuity thresholds (20/20 in the general cohort, 20/25 in the glaucoma cohort) — shown here exactly as each study reported it, not adjusted to a common scale.
Both studies also reported strong refractive predictability — 100% of eyes in each study landed within ±0.5D of the intended correction and within ±0.5D of residual astigmatism. Neither study, however, published a defocus curve, so there is no independently verified data on visual acuity across the full range of intermediate distances (as opposed to the single 40 cm near point tested), unlike the FDA SSED-based reviews of PureSee, Synergy, and PanOptix on this site.
Spectacle independence at near
Both studies asked whether patients still needed glasses for near tasks after surgery — a more direct, patient-relevant measure than acuity alone.
These figures come from patients' self-reports rather than a standardized, validated questionnaire (such as the PRVSQv2 instrument used in some FDA registration trials) — both papers note this explicitly as a limitation of their own methodology.
Halos, and what's missing from this picture
Dysphotopsia (halos, glare, and starbursts) is the central trade-off for any lens that redistributes light across multiple focal points, so it's worth being direct about what is and isn't measured here.
Neither study reported separate glare or starburst rates, neither used a validated dysphotopsia questionnaire, and neither collected contrast sensitivity data at all — a real gap for a lens whose whole design rationale (shallower echelette steps) is specifically about reducing light scatter compared with earlier diffractive designs. The manufacturer's own "Data on File" figures (93% reporting no or only mild dysphotopsia symptoms) may turn out to be broadly consistent with the picture here, but that specific claim has not been independently published in a form this page can verify.
Possible limitations, based on this data
- No FDA SSED with full registration-trial tables has been published for Odyssey as of this writing — the two studies used here are smaller, shorter, and industry-funded, not the large randomized trial data available for PureSee, Synergy, PanOptix, and Vivity on this site.
- Both studies are short-term (44 and 68 days average follow-up) and single-site — there is not yet independently published data on Odyssey outcomes at 6 or 12 months.
- Neither study reported contrast sensitivity or a defocus curve — meaning there's no independently verified picture of intermediate-distance performance or low-light contrast trade-offs for this lens yet.
- Spectacle-independence and halo figures came from unstructured patient self-report, not a validated questionnaire, in both studies.
- One study population was specifically patients with mild-to-moderate glaucoma, which may not generalize to a general cataract population, and vice versa for the other study.
- Both studies were funded by an investigator-initiated grant from Johnson & Johnson, the lens's manufacturer — peer-reviewed and disclosed, but not fully independent of the company with a commercial interest in the result.
Who this lens may suit
Based on the data available so far, Odyssey looks like a reasonable candidate for patients drawn to a full-range, diffractive-style lens who want to discuss with their surgeon how its newer echelette design compares with earlier-generation diffractive multifocal or trifocal lenses on night vision — while going in aware that the independently published evidence base for this specific lens is still thinner and shorter-term than for some established alternatives. It may be a reasonable option to raise specifically for patients with mild glaucoma, since one of the two available studies specifically included that population and found comparable outcomes to the general cohort described above.
How it compares
Odyssey sits in the same broad full-range/diffractive-EDOF category as TECNIS Synergy and Alcon PanOptix on this site, aiming to reduce spectacle dependence across all three distances rather than trading near vision away entirely, as an enhanced monofocal or non-diffractive EDOF lens like Vivity does. Where it differs from Synergy and PanOptix, based on manufacturer design claims, is a newer echelette geometry intended to lower halo/glare rates — a claim this page cannot yet verify against the same independent, large-sample FDA data available for those two lenses. For the broader category comparison, see Full Range / Trifocal IOLs.
A note on this review
This page is educational content, not a clinical trial result and not a personal recommendation. Every figure above is sourced directly from two peer-reviewed, published studies, cited by name and DOI, rather than from unverifiable manufacturer marketing material — but those studies are themselves smaller and shorter-term than the FDA registration-trial data used elsewhere on this site, and that difference is described plainly throughout rather than smoothed over. Actual outcomes vary from patient to patient, and the right lens for you can only be determined by a qualified ophthalmic surgeon based on your individual eye measurements and health history.
Sources: Keahi CL, et al. "Clinical Outcomes Following Bilateral Implantation of TECNIS Odyssey IOL." Clin Ophthalmol. 2026;20:610351. DOI: 10.2147/OPTH.S610351. — Keahi CL, Yuen C, Yuen CK, Dunn AK, Hall B, Yuen C, Tokunaga J. "Clinical Outcomes Following Bilateral Implantation of a Next-Generation IOL in Glaucoma Patients." Clin Ophthalmol. 2026;20:616773. DOI: 10.2147/OPTH.S616773.